Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Aug 7;94(31):e1298. doi: 10.1097/MD.0000000000001298

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0

PMC Copyright notice

(A) There is statistically significant difference in the overall survival (OS) of patients depending on the type of frontline therapeutic regimen (P < 0.001). However, no difference in OS was detected in patients receiving gemcitabine-based versus fluoropyrimidine-based combination therapy. (B) The impact of different therapies on OS in advanced pancreatic patients. Patients treated by chemotherapy or concurrent chemoradiotherapy had significantly longer lifespans than those who received best supportive care (P < 0.001). (C) In elderly patients (>70 years old), there is no significant difference in the OS with respect to different therapeutic strategies.